Capital International Ltd. CA Takes $2.64 Million Position in Ascendis Pharma A/S (NASDAQ:ASND)

Capital International Ltd. CA acquired a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 19,153 shares of the biotechnology company's stock, valued at approximately $2,637,000.

Several other hedge funds have also made changes to their positions in the stock. Rice Hall James & Associates LLC raised its holdings in Ascendis Pharma A/S by 2.0% in the 4th quarter. Rice Hall James & Associates LLC now owns 163,888 shares of the biotechnology company's stock valued at $22,562,000 after acquiring an additional 3,274 shares in the last quarter. abrdn plc lifted its position in Ascendis Pharma A/S by 18.3% in the fourth quarter. abrdn plc now owns 187,180 shares of the biotechnology company's stock worth $25,769,000 after purchasing an additional 28,967 shares during the period. Exome Asset Management LLC boosted its stake in Ascendis Pharma A/S by 119.2% during the third quarter. Exome Asset Management LLC now owns 43,849 shares of the biotechnology company's stock worth $6,547,000 after buying an additional 23,849 shares in the last quarter. GAMMA Investing LLC increased its holdings in Ascendis Pharma A/S by 58.0% in the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock valued at $80,000 after buying an additional 214 shares during the period. Finally, Blue Trust Inc. raised its stake in shares of Ascendis Pharma A/S by 540.5% in the 4th quarter. Blue Trust Inc. now owns 506 shares of the biotechnology company's stock valued at $76,000 after buying an additional 427 shares in the last quarter.

Ascendis Pharma A/S Stock Performance

ASND traded down $3.90 during trading on Monday, reaching $161.15. 691,086 shares of the company's stock were exchanged, compared to its average volume of 482,624. The company's fifty day moving average price is $152.70 and its 200-day moving average price is $138.25. The firm has a market capitalization of $9.83 billion, a PE ratio of -22.70 and a beta of 0.54. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $169.37.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, topping analysts' consensus estimates of ($1.32) by $0.64. Research analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ASND has been the topic of a number of analyst reports. The Goldman Sachs Group upped their target price on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. JPMorgan Chase & Co. upped their price target on Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an "overweight" rating in a research report on Tuesday, March 18th. Royal Bank of Canada started coverage on shares of Ascendis Pharma A/S in a research note on Wednesday, April 16th. They issued an "outperform" rating and a $205.00 target price on the stock. Cantor Fitzgerald boosted their price target on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an "overweight" rating in a research report on Tuesday, February 25th. Finally, Morgan Stanley set a $180.00 price objective on shares of Ascendis Pharma A/S in a report on Tuesday, February 18th. Two equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $204.67.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.